Undisclosed (Discovery Stage)

About Seranova Bio

Seranova Bio is an early-stage biotech harnessing the therapeutic potential of naturally occurring autoantibodies. Its core innovation is the REAP (Rapid Exoproteome Antigen Profiling) platform, a high-throughput, barcoded yeast display system that sensitively detects autoantibodies against correctly folded extracellular proteins. By combining this rich dataset with machine learning via its Seravista engine, Seranova identifies autoantibody reactivities correlated with improved disease outcomes, which it then develops into novel biologic drugs. The company is backed by Foresite Capital and founded by Yale immunologist Dr. Aaron Ring, positioning it to build a pipeline of antibody therapeutics inspired by human immune responses.

About Seranova Bio

Seranova Bio is an early-stage biotech harnessing the therapeutic potential of naturally occurring autoantibodies. Its core innovation is the REAP (Rapid Exoproteome Antigen Profiling) platform, a high-throughput, barcoded yeast display system that sensitively detects autoantibodies against correctly folded extracellular proteins. By combining this rich dataset with machine learning via its Seravista engine, Seranova identifies autoantibody reactivities correlated with improved disease outcomes, which it then develops into novel biologic drugs. The company is backed by Foresite Capital and founded by Yale immunologist Dr. Aaron Ring, positioning it to build a pipeline of antibody therapeutics inspired by human immune responses.

About Seranova Bio

Seranova Bio is an early-stage biotech harnessing the therapeutic potential of naturally occurring autoantibodies. Its core innovation is the REAP (Rapid Exoproteome Antigen Profiling) platform, a high-throughput, barcoded yeast display system that sensitively detects autoantibodies against correctly folded extracellular proteins. By combining this rich dataset with machine learning via its Seravista engine, Seranova identifies autoantibody reactivities correlated with improved disease outcomes, which it then develops into novel biologic drugs. The company is backed by Foresite Capital and founded by Yale immunologist Dr. Aaron Ring, positioning it to build a pipeline of antibody therapeutics inspired by human immune responses.

Therapeutic Areas